Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine

a meta-analysis

Akiyoshi Kasuga, Yasuo Hamamoto, Ayano Takeuchi, Naohiro Okano, Kazuhiro Togasaki, Yu Aoki, Takeshi Suzuki, Kenta Kawasaki, Kenro Hirata, Yasutaka Sukawa, Takanori Kanai, Hiromasa Takaishi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Summary: Background Post-progression survival (PPS) could be a confounding element in interpreting data from clinical trials of second-line chemotherapy in patients with advanced pancreatic cancer (PC) previously treated with gemcitabine (GEM) because a recent meta-analysis of oxaliplatin combination therapy showed statistical heterogeneity for overall survival (OS) but not for progression-free survival (PFS). This study aimed to improve the understanding of the impact of PPS on OS in this setting. Methods Databases were searched to identify randomized controlled trials (RCTs) in the salvage setting. We evaluated relationships between OS and PFS, PPS, and other variables. Results Totally, 17 RCTs with 3253 patients were identified. Median OS was strongly and moderately associated with median PPS and PFS, respectively (r = 0.913; p < 0.001 and 0.780; p < 0.001, respectively). The proportion of patients with good performance status was significantly associated with both PPS and PFS (r = 0.574, p < 0.001 and 0.492, p < 0.001, respectively). The induction rate of subsequent chemotherapy was related to the duration of PPS and OS (r = 0.640, p < 0.001 and 0.647, p < 0.001, respectively). Median PPS and OS were significantly longer in recent trials than those in older trials (3.55 versus 2.78 months, p < 0.001 and 6.29 versus 5.02 months, p < 0.001). Conclusions Median PPS was strongly correlated with median OS. Given the recently increased opportunity for subsequent chemotherapy and supportive care, PPS may serve as an important element to clarify problems in this setting.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalInvestigational New Drugs
DOIs
Publication statusAccepted/In press - 2018 Mar 23

Fingerprint

gemcitabine
Pancreatic Neoplasms
Meta-Analysis
Drug Therapy
Survival
Disease-Free Survival
oxaliplatin

Keywords

  • Meta-analysis
  • Pancreatic cancer
  • Post-progression survival
  • Randomized controlled trial
  • Salvage chemotherapy
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine : a meta-analysis. / Kasuga, Akiyoshi; Hamamoto, Yasuo; Takeuchi, Ayano; Okano, Naohiro; Togasaki, Kazuhiro; Aoki, Yu; Suzuki, Takeshi; Kawasaki, Kenta; Hirata, Kenro; Sukawa, Yasutaka; Kanai, Takanori; Takaishi, Hiromasa.

In: Investigational New Drugs, 23.03.2018, p. 1-10.

Research output: Contribution to journalArticle

@article{6e89c2424f284abc8ea653d91e319df6,
title = "Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis",
abstract = "Summary: Background Post-progression survival (PPS) could be a confounding element in interpreting data from clinical trials of second-line chemotherapy in patients with advanced pancreatic cancer (PC) previously treated with gemcitabine (GEM) because a recent meta-analysis of oxaliplatin combination therapy showed statistical heterogeneity for overall survival (OS) but not for progression-free survival (PFS). This study aimed to improve the understanding of the impact of PPS on OS in this setting. Methods Databases were searched to identify randomized controlled trials (RCTs) in the salvage setting. We evaluated relationships between OS and PFS, PPS, and other variables. Results Totally, 17 RCTs with 3253 patients were identified. Median OS was strongly and moderately associated with median PPS and PFS, respectively (r = 0.913; p < 0.001 and 0.780; p < 0.001, respectively). The proportion of patients with good performance status was significantly associated with both PPS and PFS (r = 0.574, p < 0.001 and 0.492, p < 0.001, respectively). The induction rate of subsequent chemotherapy was related to the duration of PPS and OS (r = 0.640, p < 0.001 and 0.647, p < 0.001, respectively). Median PPS and OS were significantly longer in recent trials than those in older trials (3.55 versus 2.78 months, p < 0.001 and 6.29 versus 5.02 months, p < 0.001). Conclusions Median PPS was strongly correlated with median OS. Given the recently increased opportunity for subsequent chemotherapy and supportive care, PPS may serve as an important element to clarify problems in this setting.",
keywords = "Meta-analysis, Pancreatic cancer, Post-progression survival, Randomized controlled trial, Salvage chemotherapy, Second-line chemotherapy",
author = "Akiyoshi Kasuga and Yasuo Hamamoto and Ayano Takeuchi and Naohiro Okano and Kazuhiro Togasaki and Yu Aoki and Takeshi Suzuki and Kenta Kawasaki and Kenro Hirata and Yasutaka Sukawa and Takanori Kanai and Hiromasa Takaishi",
year = "2018",
month = "3",
day = "23",
doi = "10.1007/s10637-018-0589-6",
language = "English",
pages = "1--10",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine

T2 - a meta-analysis

AU - Kasuga, Akiyoshi

AU - Hamamoto, Yasuo

AU - Takeuchi, Ayano

AU - Okano, Naohiro

AU - Togasaki, Kazuhiro

AU - Aoki, Yu

AU - Suzuki, Takeshi

AU - Kawasaki, Kenta

AU - Hirata, Kenro

AU - Sukawa, Yasutaka

AU - Kanai, Takanori

AU - Takaishi, Hiromasa

PY - 2018/3/23

Y1 - 2018/3/23

N2 - Summary: Background Post-progression survival (PPS) could be a confounding element in interpreting data from clinical trials of second-line chemotherapy in patients with advanced pancreatic cancer (PC) previously treated with gemcitabine (GEM) because a recent meta-analysis of oxaliplatin combination therapy showed statistical heterogeneity for overall survival (OS) but not for progression-free survival (PFS). This study aimed to improve the understanding of the impact of PPS on OS in this setting. Methods Databases were searched to identify randomized controlled trials (RCTs) in the salvage setting. We evaluated relationships between OS and PFS, PPS, and other variables. Results Totally, 17 RCTs with 3253 patients were identified. Median OS was strongly and moderately associated with median PPS and PFS, respectively (r = 0.913; p < 0.001 and 0.780; p < 0.001, respectively). The proportion of patients with good performance status was significantly associated with both PPS and PFS (r = 0.574, p < 0.001 and 0.492, p < 0.001, respectively). The induction rate of subsequent chemotherapy was related to the duration of PPS and OS (r = 0.640, p < 0.001 and 0.647, p < 0.001, respectively). Median PPS and OS were significantly longer in recent trials than those in older trials (3.55 versus 2.78 months, p < 0.001 and 6.29 versus 5.02 months, p < 0.001). Conclusions Median PPS was strongly correlated with median OS. Given the recently increased opportunity for subsequent chemotherapy and supportive care, PPS may serve as an important element to clarify problems in this setting.

AB - Summary: Background Post-progression survival (PPS) could be a confounding element in interpreting data from clinical trials of second-line chemotherapy in patients with advanced pancreatic cancer (PC) previously treated with gemcitabine (GEM) because a recent meta-analysis of oxaliplatin combination therapy showed statistical heterogeneity for overall survival (OS) but not for progression-free survival (PFS). This study aimed to improve the understanding of the impact of PPS on OS in this setting. Methods Databases were searched to identify randomized controlled trials (RCTs) in the salvage setting. We evaluated relationships between OS and PFS, PPS, and other variables. Results Totally, 17 RCTs with 3253 patients were identified. Median OS was strongly and moderately associated with median PPS and PFS, respectively (r = 0.913; p < 0.001 and 0.780; p < 0.001, respectively). The proportion of patients with good performance status was significantly associated with both PPS and PFS (r = 0.574, p < 0.001 and 0.492, p < 0.001, respectively). The induction rate of subsequent chemotherapy was related to the duration of PPS and OS (r = 0.640, p < 0.001 and 0.647, p < 0.001, respectively). Median PPS and OS were significantly longer in recent trials than those in older trials (3.55 versus 2.78 months, p < 0.001 and 6.29 versus 5.02 months, p < 0.001). Conclusions Median PPS was strongly correlated with median OS. Given the recently increased opportunity for subsequent chemotherapy and supportive care, PPS may serve as an important element to clarify problems in this setting.

KW - Meta-analysis

KW - Pancreatic cancer

KW - Post-progression survival

KW - Randomized controlled trial

KW - Salvage chemotherapy

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85044378970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044378970&partnerID=8YFLogxK

U2 - 10.1007/s10637-018-0589-6

DO - 10.1007/s10637-018-0589-6

M3 - Article

SP - 1

EP - 10

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

ER -